WO1997027851A1 - L-homoserine and l-homoserine lactone as bacteriostatic agents for m. tuberculosis and m. bovis - Google Patents
L-homoserine and l-homoserine lactone as bacteriostatic agents for m. tuberculosis and m. bovis Download PDFInfo
- Publication number
- WO1997027851A1 WO1997027851A1 PCT/US1997/001241 US9701241W WO9727851A1 WO 1997027851 A1 WO1997027851 A1 WO 1997027851A1 US 9701241 W US9701241 W US 9701241W WO 9727851 A1 WO9727851 A1 WO 9727851A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- homoserine
- mycobacterium
- tuberculosis
- growth
- slow growing
- Prior art date
Links
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 title claims abstract description 196
- QJPWUUJVYOJNMH-VKHMYHEASA-N L-homoserine lactone Chemical compound N[C@H]1CCOC1=O QJPWUUJVYOJNMH-VKHMYHEASA-N 0.000 title claims abstract description 81
- QJPWUUJVYOJNMH-UHFFFAOYSA-N alpha-amino-gamma-butyrolactone Natural products NC1CCOC1=O QJPWUUJVYOJNMH-UHFFFAOYSA-N 0.000 title claims abstract description 60
- 201000008827 tuberculosis Diseases 0.000 title claims abstract description 58
- 239000000022 bacteriostatic agent Substances 0.000 title description 3
- 241000589343 Methylobacter luteus Species 0.000 title 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 claims abstract description 105
- 238000000034 method Methods 0.000 claims abstract description 39
- 239000002243 precursor Substances 0.000 claims abstract description 21
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 20
- 108090000623 proteins and genes Proteins 0.000 claims description 32
- 241000186359 Mycobacterium Species 0.000 claims description 29
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 claims description 22
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 17
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 claims description 14
- 241000894007 species Species 0.000 claims description 14
- 230000001105 regulatory effect Effects 0.000 claims description 12
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 12
- 229960000285 ethambutol Drugs 0.000 claims description 11
- 239000003926 antimycobacterial agent Substances 0.000 claims description 9
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 claims description 9
- 229960003350 isoniazid Drugs 0.000 claims description 7
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims description 6
- 229960005322 streptomycin Drugs 0.000 claims description 6
- FXDNYOANAXWZHG-VKHMYHEASA-N O-phospho-L-homoserine Chemical group OC(=O)[C@@H](N)CCOP(O)(O)=O FXDNYOANAXWZHG-VKHMYHEASA-N 0.000 claims description 5
- 229960001225 rifampicin Drugs 0.000 claims description 5
- 229940034014 antimycobacterial agent Drugs 0.000 claims description 4
- 241000186367 Mycobacterium avium Species 0.000 claims description 3
- 229960005206 pyrazinamide Drugs 0.000 claims description 3
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 2
- 230000004044 response Effects 0.000 claims description 2
- 241001314546 Microtis <orchid> Species 0.000 claims 4
- 241000186363 Mycobacterium kansasii Species 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 239000002609 medium Substances 0.000 description 30
- 150000001875 compounds Chemical class 0.000 description 25
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 23
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 21
- 229930195712 glutamate Natural products 0.000 description 21
- 230000000694 effects Effects 0.000 description 18
- 241000894006 Bacteria Species 0.000 description 17
- UKAUYVFTDYCKQA-GSVOUGTGSA-N D-homoserine Chemical compound OC(=O)[C@H](N)CCO UKAUYVFTDYCKQA-GSVOUGTGSA-N 0.000 description 15
- 229920001817 Agar Polymers 0.000 description 11
- 239000008272 agar Substances 0.000 description 11
- 230000003385 bacteriostatic effect Effects 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- 230000009036 growth inhibition Effects 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 244000052616 bacterial pathogen Species 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 229940035893 uracil Drugs 0.000 description 8
- 210000002540 macrophage Anatomy 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000001332 colony forming effect Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000010348 incorporation Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000003298 DNA probe Substances 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- YRYOXRMDHALAFL-UHFFFAOYSA-N N-(3-oxohexanoyl)homoserine lactone Chemical compound CCCC(=O)CC(=O)NC1CCOC1=O YRYOXRMDHALAFL-UHFFFAOYSA-N 0.000 description 4
- 241000463316 Phyllastrephus fischeri Species 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 4
- 229960003077 cycloserine Drugs 0.000 description 4
- 239000010432 diamond Substances 0.000 description 4
- 229910003460 diamond Inorganic materials 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 239000002054 inoculum Substances 0.000 description 4
- 229930182817 methionine Natural products 0.000 description 4
- 201000009671 multidrug-resistant tuberculosis Diseases 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 108020003215 DNA Probes Proteins 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 230000005526 G1 to G0 transition Effects 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000002814 agar dilution Methods 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000029918 bioluminescence Effects 0.000 description 3
- 238000005415 bioluminescence Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000003365 glass fiber Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000009630 liquid culture Methods 0.000 description 3
- 101150016512 luxR gene Proteins 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000003802 sputum Anatomy 0.000 description 3
- 208000024794 sputum Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical class O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 description 2
- 241000220479 Acacia Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 241000186366 Mycobacterium bovis Species 0.000 description 2
- 241000187480 Mycobacterium smegmatis Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 230000001355 anti-mycobacterial effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 229930188620 butyrolactone Natural products 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- -1 homoserine lactones Chemical class 0.000 description 2
- 244000052637 human pathogen Species 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 244000039328 opportunistic pathogen Species 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- VFFNZZXXTGXBOG-LURJTMIESA-N (+)-a(S)-butyr-amido-r-butyrolactone Chemical compound CCCC(=O)N[C@H]1CCOC1=O VFFNZZXXTGXBOG-LURJTMIESA-N 0.000 description 1
- REAWNMHCBIUKLZ-ZYHUDNBSSA-N (3R,4R)-4-(hydroxymethyl)-3-(6-methylheptanoyl)oxolan-2-one Chemical compound CC(C)CCCCC(=O)[C@H]1[C@H](CO)COC1=O REAWNMHCBIUKLZ-ZYHUDNBSSA-N 0.000 description 1
- FIXDIFPJOFIIEC-RITPCOANSA-N (3r)-3-hydroxy-n-[(3s)-2-oxooxolan-3-yl]butanamide Chemical compound C[C@@H](O)CC(=O)N[C@H]1CCOC1=O FIXDIFPJOFIIEC-RITPCOANSA-N 0.000 description 1
- FXCMGCFNLNFLSH-JTQLQIEISA-N 3-oxo-octanoic acid (2-oxo-tetrahydro-furan-3-yl)-amide Chemical compound CCCCCC(=O)CC(=O)N[C@H]1CCOC1=O FXCMGCFNLNFLSH-JTQLQIEISA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000589158 Agrobacterium Species 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000238366 Cephalopoda Species 0.000 description 1
- 241000581444 Clinidae Species 0.000 description 1
- 206010013709 Drug ineffective Diseases 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 102100024020 Guanine nucleotide-binding protein-like 1 Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000904099 Homo sapiens Guanine nucleotide-binding protein-like 1 Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 125000001135 L-homoserine lactone group Chemical group O1C(=O)[C@](N([H])[*])([H])C([H])([H])C1([H])[H] 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 239000001971 Middlebrook 7H10 Agar Substances 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 206010062207 Mycobacterial infection Diseases 0.000 description 1
- 241001508003 Mycobacterium abscessus Species 0.000 description 1
- 241000186364 Mycobacterium intracellulare Species 0.000 description 1
- 241000186362 Mycobacterium leprae Species 0.000 description 1
- 241001646725 Mycobacterium tuberculosis H37Rv Species 0.000 description 1
- 241001302239 Mycobacterium tuberculosis complex Species 0.000 description 1
- 241000187644 Mycobacterium vaccae Species 0.000 description 1
- PHSRRHGYXQCRPU-AWEZNQCLSA-N N-(3-oxododecanoyl)-L-homoserine lactone Chemical compound CCCCCCCCCC(=O)CC(=O)N[C@H]1CCOC1=O PHSRRHGYXQCRPU-AWEZNQCLSA-N 0.000 description 1
- ZJFKKPDLNLCPNP-QMMMGPOBSA-N N-[(3s)-2-Oxotetrahydrofuran-3-Yl]hexanamide Chemical compound CCCCCC(=O)N[C@H]1CCOC1=O ZJFKKPDLNLCPNP-QMMMGPOBSA-N 0.000 description 1
- VFFNZZXXTGXBOG-UHFFFAOYSA-N N-butanoyl-L-homoserine lactone Natural products CCCC(=O)NC1CCOC1=O VFFNZZXXTGXBOG-UHFFFAOYSA-N 0.000 description 1
- ZJFKKPDLNLCPNP-UHFFFAOYSA-N N-hexanoyl-L-homoserine lactone Natural products CCCCCC(=O)NC1CCOC1=O ZJFKKPDLNLCPNP-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- FXCMGCFNLNFLSH-UHFFFAOYSA-N OOHL Natural products CCCCCC(=O)CC(=O)NC1CCOC1=O FXCMGCFNLNFLSH-UHFFFAOYSA-N 0.000 description 1
- 241001464887 Parvimonas micra Species 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 241000588701 Pectobacterium carotovorum Species 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 241000607568 Photobacterium Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 101100074223 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) lasR gene Proteins 0.000 description 1
- 241000015473 Schizothorax griseus Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000036981 active tuberculosis Diseases 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 150000004665 fatty acids Chemical group 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000035990 intercellular signaling Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- NSXYYYUKWBLFQH-MHECFPHRSA-N methyl (2r)-4-hydroxy-2-[[(3s)-3-hydroxy-2,2-dimethyl-3,4-dihydrochromen-6-yl]methyl]-3-(4-hydroxyphenyl)-5-oxofuran-2-carboxylate Chemical compound O([C@@]1(CC=2C=C3C[C@H](O)C(C)(C)OC3=CC=2)C(=O)OC)C(=O)C(O)=C1C1=CC=C(O)C=C1 NSXYYYUKWBLFQH-MHECFPHRSA-N 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- 239000004223 monosodium glutamate Substances 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 description 1
- 230000003406 mycobactericidal effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000008560 physiological behavior Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 210000003859 smegma Anatomy 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000001768 subcellular fraction Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002723 toxicity assay Methods 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 239000000814 tuberculostatic agent Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
Definitions
- M. tuberculosis and M. b ⁇ vis are two species of mycobacteria that cause tuberculosis .
- M. tuberculosis is resistant to the enzyme activities of neutrophils and/or macrophages. As a result, M. tuberculosis survives, continuing to grow and later to cause infection because of the failure of these phagocytic cells to kill the invading pathogens.
- Treatment of tuberculosis is based upon intensive and prolonged exposure of the organisms to bacterial antagonists such as antibiotics. However, drug resistance is a significant problem.
- MDRTB multidrug resistant tuberculosis
- DNA probe hybridization is the current state- of-the-art technology for species identification once an isolate has been grown up in the standard cultivation medium.
- the DNA probe test is expensive, difficult to perform in developing countries, and requires an additional day of testing beyond the 3-6 additional days required to grow the isolate to sufficient levels.
- a method for inhibiting growth of slow growing mycobacteria which comprises administering to said mycobacteria an inhibiting amount of L- homoserine, L-homoserine lactone or a precursor thereof.
- a method for identifying slow growing mycobacteria comprises inoculating a clinical specimen into a cultivation medium in the presence of and in the absence of L-homoserine, L-homoserine lactone or a precursor thereof. If the specimen grows in the cultivation medium in the absence of these compounds, but not in the medium which contains the compounds, the presence of a slow growing mycobacterium is indicated.
- Preferred slow growing mycobacteria that are targets of the invention are tuberculous mycobacteria and non-tuberculous mycobacteria.
- Tuberculous mycobacteria include M. tuberculosis , M. bovis , M. africanuum, and M. micro ti ; non- tuberculous mycobacteria include M. avium, M. intracellulare, M. kan ⁇ asii , and M. leprae .
- the compounds of the present invention act by a mechanism which is different from those characterized for known anti-mycobacterial agents, a combination of the different classes of anti-mycobacterial agents provides a composition useful for inhibiting growth of slow growing mycobacteria.
- a method for identifying targets of L- homoserine, L-homoserine lactone, or a precursor thereof that cause growth inhibition is provided by the invention.
- the present invention provides the art with methods of using compounds which are specifically bacteriostatic for slow growing mycobacteria.
- This invention thus provides methods for identifying and treating tuberculosis, especially tuberculosis caused by multidrug resistant M. tuberculosis .
- This invention also provides an inexpensive, simple and quick diagnostic test which distinguishes slow growing mycobacteria, including M. tuberculosis complex organisms, from non-tuberculous, rapid growing mycobacteria in the clinical laboratory.
- the invention provides a mycobacterial cell line resistant to growth inhibition by L- homoserine, L-homoserine lactone, or a precursor thereof useful as a control in the methods of the invention.
- Figure 1 illustrates the metabolic biosynthesis of homoserine, homoserine phosphate, and homoserine lactone. Enzymes that control each step of the metabolic pathway are shown beneath the reaction arrows.
- Figure 2 shows chemical compounds useful in understanding the present invention.
- Figure 3 shows growth-inhibited ⁇ f. bovis BCG exposed to L-homoserine lactone are still metabolically active as measured by continued utilization of uracil.
- Panel A shows treatment with 50 ⁇ g/ml
- panel B shows treatment with 100 ⁇ g/ml
- panel C shows treatment with 200 ⁇ g/ml for medium alone (square) , L-homoserine lactone (circle) , and L-homoserine (diamond) .
- the abscissa is time of treatment in days, and the ordinate is counts per 4 min.
- Figure 4 shows inhibition of ⁇ f.
- D-homoserine is shown in panels A, C and E at 50 ⁇ g/ml (diamond) or 200 ⁇ g/ml (circle) ;
- L-homoserine is shown in panels B, D and F at 50 ⁇ g/ml (diamond) or 200 ⁇ g/ml (circle) ;
- controls are medium alone (square) and D- cycloserine at 50 ⁇ g/ml (triangle) .
- the abscissa is time in days, and the ordinate is counts per 4 min.
- Figure 5 shows survival of ⁇ f.
- bovis BCG after homoserine or homoserine lactone treatment From top to bottom: square represents phosphate-buffered saline, diamond represents D-homoserine, circle represents L-homoserine, triangle represents L- homoserine lactone, inverted triangle represents ethambutol, and asterisk represents isoniazid.
- the abscissa is time of treatment in days, and the ordinate is colony forming units per milliliter.
- Figure 6 shows specific inhibition by L- homoserine of glutamate uptake in wild type ⁇ f. bovis BCG and L-homoserine resistant ⁇ f. Jbovis BCG.
- Panel A illustrates glutamate uptake in wild type M. bovis BCG determined against increasing concentrations of L-homoserine (filled square) or D-homoserine (open square) . The dpms obtained from the experimental samples were normalized to controls. When the value was greater than a hundred, 100% was used.
- Panel B glutamate uptake in the presence of 200 ⁇ g/ml L- homoserine in wild type ⁇ f. Jbovis BCG as well as two L-homoserine resistant ⁇ f. Jbovis BCG strains. The error bar indicates the standard deviation for each strain tested.
- L-homoserine and its metabolites can inhibit the growth of slow growing mycobacteria.
- these compounds are specifically bacteriostatic for slow growing mycobacteria including ⁇ f. tuberculosis, multidrug resistant isolates of ⁇ f. tuberculosis, and ⁇ f. bovis .
- This discovery provides the basis for using these compounds therapeutically to alleviate clinical infections and diagnostically to identify whether a potentially pathogenic species is present.
- Compounds which may be used according to the present invention include homoserine, homoserine lactone, and precursors thereof.
- the precursors are compounds that can be converted to L-homoserine or L-homoserine lactone under the conditions known in the art (see Figure 1) .
- the precursors include L- homoserine phosphate.
- the bacteria which are susceptible to growth inhibition by homoserine and its metabolites are mycobacteria.
- Mycobacteria are slender, straight or curved rods. They usually occur singly or in clusters but may occasionally exhibit a branching and filamentous form.
- Mycobacteria are well characterized in the art. They are usually acid fast and grow on ordinary medium known in the art. The time interval required for the cell to divide or for the population to double is known as the generation time. Not all bacteria have the same generation time; for some rapid growers, such as E. coli , it is 15 to 20 minutes; for others it is hours. Slow growing mycobacteria have a generation time of at least 10 hours; for ⁇ f. tuberculosis, and for ⁇ f.
- mycobacterial mutants have been isolated and have been the subject of intensive study. Mutation can, and often does, result in an increased tolerance to inhibitory agents, particularly antibiotics.
- mycobacteria alter genetic determinants encoding enzymes involved in the mechanism of action of the antibiotic rendering the drug ineffective.
- Multidrug resistant ⁇ f. tuberculosis are those bacteria that have become resistant to two or more antibiotics either by mutation or by acquisition of drug resistance determinants.
- an autoinducer is a small diffusible molecule which is produced and then secreted by a microorganism during metabolism and which then acts to increase or decrease the expression of the genes of the microorganism.
- Autoinducers may be synthesized by adding a fatty acid chain to a L- homoserine lactone ( Figure 2) . L-homoserine lactone is widespread in bacteria.
- Known autoinducers include L-homoserine lactone derivatives or modified L-homoserine lactones including N-acyl-L-homoserine lactones such as N- (3-oxohexanoy1) -L-homoserine lactone, N- (3 -hydroxybutanoyl) -L-homoserine lactone, N- (3 -oxododecanoyl) -L-homoserine lactone, N- (3- oxooctanoyl) -L-homoserine lactone, N-butanoyl-L- homoserine lactone, and N-hexanoyl-L-homoserine lactone.
- N-acyl-L-homoserine lactones such as N- (3-oxohexanoy1) -L-homoserine lactone, N- (3 -hydroxybutanoyl) -L-homoser
- PCT Publication WO 92/18614 describes various members of this family of compounds, including optically active isomers thereof.
- Precursors of autoinducers can be used by the enzymes of a microorganism to produce autoinducers .
- Bacteria use autoinducers to communicate intercellularly. These autoinducers function as quorum sensors in certain bacteria and, when present at sufficient concentrations, activate regulatory cascades leading to the transcription of genes associated with high density growth.
- P. fischeri grows to densities of IO 11 cfu/ml within the light organs of certain marine fish and squids.
- OHHL produced by the organism reaches a critical concentration which leads to the activation of bioluminescence genes and light production (Eberhard, J. Bacteriol., 109:1101-1105, 1972; Kaplan and Greenberg, J.
- the molecular genetics of autoinducer biosynthesis and subsequent gene activation in P. fischeri is controlled by luxl and luxR genes.
- the gene product of luxl is responsible for the synthesis of OHHL and LuxR is the receptor for the autoinducer. Once the autoinducer is bound, LuxR becomes a transcriptional activator that activates genes involved in bioluminescence production (Fuqua et al., J. Bacteriol., 176:269-275, 1994) .
- the autoinducers produced by different bacteria are species-specific. Gram-positive bacterium Strepto yces spp . produce butyrolactones rather than homoserine lactones as their autoinducers (Horinouchi and Beppu, Annu. Rev. Microbiol., 46:377-398, 1992) . Increasing concentrations of A-factor, a butyrolactone derivative ( Figure 2) , in stationary phase trigger morphological and biochemical changes in S . griseus leading to sporolation and the production of streptomycin (Horinouchi et al. , J. Bacteriol., 171:1206-1210, 1989; Beppu, Gene, 115:159-165, 1992) . In addition to intercellular signaling with
- N-acyl-L-homoserine lactones or butyrolactones other bacteria such as Escherichia coli are believed to use non-acylated L-homoserine lactone itself as an intracellular signaling molecule.
- L- homoserine lactone accumulates in stationary phase and is believed to stimulate the production of RpoS, a major regulatory protein for stationary phase survival.
- L-homoserine is the intermediate in the biosynthesis of methionine, threonine, and isoleucine from aspartate
- homoserine lactone is the byproduct of the synthetic pathway ( Figure 1) .
- Huis an and Kolter Science, 265:537-539, 1994
- L-homoserine lactone could accumulate intracellularly in response to early amino acid deficiencies and thus provide an early warning signal for impending starvation.
- L-homoserine inhibits growth of Mycobacterium smegmatis - a non- pathogenic rapid grower; the mechanism for growth inhibition is thought to be a blockade in glutamate uptake by L-homoserine (Sritharan et al. , J. Gen. Microbiol., 133:2781-2785, 1987) .
- L-homoserine is also toxic for slow growing mycobacteria in culture by a bacteriostatic mechanism. However, its effect on glutamate uptake in ⁇ f. bovis BCG cannot account for the growth inhibition observed.
- the invention compounds are employed to inhibit the growth of slow growing mycobacteria including ⁇ f. Jbovis, M. tuberculosis, and multidrug resistant ⁇ f. tuberculosis .
- a mammal infected with slow growing mycobacteria can be treated with an effective amount of L-homoserine, L- homoserine lactone or a precursor thereof.
- an effective amount of these compounds is administered to a human infected with ⁇ f. tuberculosis, ⁇ f. bovis or multidrug resistant isolates of ⁇ f. tuberculosis. This treatment kills or inhibits the growth of ⁇ f. tuberculosis, M.
- the invention may also be effective in treating disease caused by rapid growing non- tuberculous mycobactaria such as, for example, ⁇ f. fortuiturn, ⁇ f. chelonae, M. abscessus, ⁇ f. peregrinum, and ⁇ f. marinum (Wright and Wallance, In: Rossman, M.D. and MacGregor, R.R., eds. Tuberculosis, Clinical Management and New Challenges . McGraw-Hill, New York, pp. 373-389, 1995) by killing or inhibiting the growth of the relevant pathogen.
- non- tuberculous mycobactaria such as, for example, ⁇ f. fortuiturn, ⁇ f. chelonae, M. abscessus, ⁇ f. peregrinum, and ⁇ f. marinum (Wright and Wallance, In: Rossman, M.D. and MacGregor, R.R., eds. Tuberculosis, Clinical Management and
- ⁇ f. bovis BCG is sometimes used to demonstrate the invention because this mycobacteria is an art-recognized model for the human pathogen ⁇ f. tuberculosis (Jacobs and Bloom, In: Bloom B.R., ed. Tuberculosis : Pathogenesis, Protection and Control , ASM Press, Washington, DC, pp. 253-268, 1994) .
- the compounds are preferably formulated prior to administration.
- Suitable pharmaceutical formulations are prepared by known procedures using well known and readily available ingredients (see Martin, E.W., Remington's Pharmaceutical Sciences , Mack Publishing, Easton, PA) .
- the formulations include those suitable for oral, parenteral
- the formulation may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired form.
- Formulations for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats, and solutes which render the formulation isotonic with the blood of the intended recipient.
- aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents may also be added.
- Formulations for topical administration in the mouth include lozenges comprising the active ingredient in a flavored bases such as sucrose and acacia or tragacanth, and pastilles comprising the active ingredient in a bases such as gelatin and glycerin, or sucrose and acacia.
- the formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question.
- the compounds of the invention may be administered orally or via injection at a dose of from about 2.5 mg/Kg body weight per day to about 2 g/Kg body weight per day. More preferably the dose would be about 25 mg/Kg body weight per day to about 200 mg/Kg body weight per day.
- the dose range for adult humans is generally from about 50 mg to about 300 g/day.
- One skilled in the art will recognize that the amount sufficient to inhibit the growth of slow growing mycobacteria varies depending upon an affected tissue size, age and body weight of the patient, and concentration of the compound in the formulation.
- Clinical specimens can be tested for the presence of slow growing mycobacteria including ⁇ f. tuberculosis according to this invention.
- the clinical specimens can include samples obtained from biopsies, blood, and body discharge such as sputum, peritoneal fluid, pleural fluid, gastric content, spinal fluid, urine, and the like.
- Clinical specimens can be inoculated into a cultivation medium.
- the mycobacteria isolate grows in standard cultivation medium but not in cultivation medium when it contains L-homoserine, L-homoserine lactone or precursors thereof, the presence of a slow growing mycobacterium is indicated and the presence of a rapid growing mycobacterium such as ⁇ f. smegmatis or M. vaccae is eliminated.
- the minimal inhibitory concentrations of L-homoserine or L- homoserine lactone for susceptible bacteria generally will range from about 22 to about 45 ⁇ g/ml in liquid cultivation medium and from about 25 to about 50 ⁇ g/ml in solid cultivation medium.
- Resistant bacteria grow well at concentrations of L- homoserine and L-homoserine lactone in excess of about 200 ⁇ g/ml.
- the preferred concentration of the added compound in the cultivation medium is from about 100 ⁇ g/ml to about 200 ⁇ g/ml for either L-homoserine or L- homoserine lactone.
- the composition and the preparation of liquid and solid cultivation medium for mycobacteria are well known in the art and are commercially available. See chapter 7 "Current Laboratory Methods for the Diagnosis of
- the solid media can be, but is not limited to, egg-based media (Lowenstein-Jensen Ogawa, and American Trudeau Society) and agar-based media (Middlebrook-Cohn 7H10 agar and 7H11 agar) .
- the liquid media can be, but is not limited to, Middlebrook 7H12 broth and 7H9 broth. Slow growing mycobacteria usually grow at 37°C and pH between about 5.8 to about 8.0.
- the cultivation medium desirably contains some incorporated antibiotics which inhibit the growth of the non-mycobacterial contaminants.
- the composition of the cultivation medium can affect the minimal inhibitory concentration.
- Animal cells in culture or bacterial cells in culture are examples of samples that may be screened for mycobacteria.
- Cell and tissue cultures are terms of art that refer to propagation in vitro of isolated animal cells, while bacterial culture refers to propagating bacteria in a liquid or solid medium in the presence or absence of host cells in vitro.
- Preferred host cells include mycobacterium- infectable cells, in particular cells of the macrophage-phagocyte lineage. Such mycobacterium- infectable cells may be identified by exposing the putative mycobacterium-infectable cell to mycobacteria, and then utilizing the methods described in this application to detect the presence of intracellular mycobacteria or their growth.
- the homoserine related compounds are employed to inhibit the growth of mycobacteria in infected macrophages, monocytes, histiocytes, Kupffer cells and microglia. These cells may be isolated from a human and cultured in vitro; in particular, alveolar macrophages may be obtained from bronchoalveolar lavage or peripheral blood macrophages .
- L-homoserine lactone can be added in a concentration of up to about 200 ⁇ g/ml to a human macrophage cell line infected with slow growing mycobacteria without toxic effect on the macrophage cells.
- a mycobacterial gene or genetic program, as well as proteins encoded by such genes, may be regulated by homoserine or homoserine lactone.
- Mycobaterial cultures may be compared prior to and after treatment with homoserine or homoserine lactone. For example, if homoserine acted as an autoinducer in mycobacteria, gene transcription may be induced or repressed by addition of homoserine to the culture.
- Homoserine regulated genes may be identified by screening a subtractive cDNA library, or by differential screening of cDNA or genomic clone libraries of mycobacteria.
- regulated transcripts will be translated into regulated proteins, such proteins may be identified by comparing the pattern of proteins expressed prior to and after treatment with homoserine or homoserine lactone.
- pre- and post-treatment cultures of mycobacteria may be pulsed with 35 S-amino acids
- protein extracts may be made from whole cell lysates or subcellular fractions
- regulated proteins may be identified by their increased or decreased signal intensity in two-dimensional gels 35 S-labeled proteins from pre- and post-treatment cultures.
- Proteins of interest i.e., labeled proteins which increase or decrease in abundance
- N-terminal or internal peptide amino acid sequence may be determined, and the regulated gene of interest identified.
- Homoserine or homoserine lactone regulated genes may also be identified by promoter trapping.
- a clone library of mycobacterial genomic DNA fragment inserted into a promoter probe vector can be constructed to operably linked the DNA fragment with an indicator gene (e.g., lacZ, luxAB, xylE, firefly luciferase, the gene for green fluorescent protein or gfp, melC) , such that a promoter contained in the DNA fragment may direct the transcription of the indicator gene.
- an indicator gene e.g., lacZ, luxAB, xylE, firefly luciferase, the gene for green fluorescent protein or gfp, melC
- a suitable indicator gene will be transcribed and produce a detectable indicator product under appropriate assay conditions. Individual clones of the library may be introduced into ⁇ f.
- DNA fragments will be isolated form colonies which produce indicator product only when homoserine or homoserine lactone is present because they could contain homoserine-dependent promoters.
- a construct containing the indicator gene but no operably linked promoter may be randomly integrated into the mycobacterial chromosome. Clones which contain integrations near homoserine-regulated promoters may be identified after addition of homoserine by screening for the indicator product . Those integrations could mark the sites of homoserine-regulated promoters and isolating the mycobacterial genes associated with such promoters may also identify homoserine-regulated genes.
- the strains of mycobacteria used were the ⁇ f. bovis BCG (Pasteur strain, ATCC #5734) , ⁇ f. tuberculosis H37Rv (ATCC 27294) , D-CS R (ATCC 35826) , ⁇ f. smegmatis mc 2 6 1-2C, a transformable variant of mc 2 6 (Zhang et al . , Mol. Microbiol., 5:381-391, 1991) , and the A4 strain of ⁇ f. avium (Cooksey et al . , Antimicrob. Agents Chemother., 39:754-756, 1995) . ⁇ f.
- tuberculosis clinical isolates were obtained from Loayza Hospital (Lima, Peru) . All mycobacterial strains were cultured in Middlebrook 7H9 broth or 7H10 agar (Difco) supplemented with 10% ADC (albumin dextrose complex) , 50 ⁇ g/ml cycloheximide (Sigma), 0.2% glycerol and 0.05% Tween 80 (7H9 broth only) . Nitrogen-depleted 7H9 medium was prepared by omitting monosodium glutamate and ammonium sulfate from the original formulation.
- Example 1 Example 1 :
- the BACTEC procedure for drug susceptibility testing of mycobacteria is based on the same principle employed in the conventional (agar) method except that a liquid medium is used. Instead of counting colonies, the growth is monitored radiometrically. Resistance is determined by comparing the rate of growth in the control and the vials containing test drug. When an antituberculous drug is added to the medium, suppression can be detected by a reduced daily growth index (GI) when compared to the control (Siddiqi, "Radiometric (BACTEC) tests for slowly growing mycobacteria.” In: Isenberg, H.D. ed. Clinical Microbiology Procedures Handbook, Vol. 1. ASM Press, Washington, DC, 1992) .
- GI Growth index
- Negative or zero ⁇ GI values indicate no growth, while positive ⁇ GI values indicate an increase in growth.
- One of the four quadrants in each plate functions as control medium without L-homoserine lactone.
- the inoculum was spread evenly in each quadrant using a sterile loop.
- the plates were air-dried and incubated at 37°C for 3 weeks for ⁇ f. bovis BCG, ⁇ f. avium, or ⁇ f. tuberculosis strains; or 5 days for ⁇ f. smegmatis .
- colonies were observed in the quadrants with 0 or 25 ⁇ g/ml L-homoserine lactone, but not in the quadrants with 50 or 100 ⁇ g/ml L- homoserine lactone; whereas, for ⁇ f. smegmatis was observed in the quadrants with L-homoserine up to 200 ⁇ g/ml.
- MIC minimal inhibitory concentration
- H37Rv M. tuberculosis
- H37Rv A commonly used laboratory strain of M. tuberculosis, H37Rv, although it is slow growing and pathogenic, was able to grow in the presence of 100 ⁇ g/ml of L-homoserine and L-homoserine lactone. Since H37Rv has been adapted in laboratories for almost a century, it may differ from clinical isolates of ⁇ f. tuberculosis in terms of its physiological behavior.
- M. tuberculosis D-CS R >100 >100 >100 50
- ⁇ f. bovis BCG-HS R 1 was sensitive to D-cycloserine with the same MIC value of 40 ⁇ g/ml as its parental ⁇ f. bovis BCG strain, indicating there is no cross resistance between L-homoserine and D-cycloserine. This observation implies that the mechanism of growth inhibition by L-homoserine against slow growing mycobacteria differs from the mechanism of action of D-cycloserine.
- strain TBL002EP2 was susceptible to all five antibiotics tested but was relatively resistant to L-homoserine; whereas TBL019EP21, an MDR isolate, was susceptible to 50 ⁇ g/ml of L-homoserine.
- Our results suggest that sensitivity to L-homoserine varies among ⁇ f. tuberculosis strains.
- Table 2 Susceptibility of clinical isolates of M. tuberculosis to L-homoserine (L-HS) , isoniazid (INH) , streptomycin (SM) , ethambutol (EMB) , rifampin (RA) , and pyrazinamide (PZA) .
- L-HS L-homoserine
- IH isoniazid
- SM streptomycin
- EMB ethambutol
- RA rifampin
- PZA pyrazinamide
- a 3 H-uracil incorporation assay was used to monitor the viability of ⁇ f. bovis BCG exposed to different concentrations of L-homoserine lactone.
- Homoserine lactone was added to final concentrations of 50, 100, and 200 ⁇ g/ml. The cultures were incubated at 37°C in 5% C0 2 for 7 days. On each day after homoserine lactone treatment, aliquots of 5 ⁇ l were removed from each well in triplicate and transferred to wells in a 96- well plate containing 195 ⁇ l 7H9 medium.
- IO 8 bacilli were diluted to IO "2 , and 0.2 ml of each suspension were aliquoted in 96-well plates.
- Stock solutions of D-homoserine, L- homoserine, or D-cycloserine (10 mg/ml prepared in PBS) were added to the ⁇ f. bovis BCG cultures and the final concentrations of these compounds were 25, 50, 100 and 200 ⁇ g/ml. Control cultures were treated with PBS only. Multiple samples were set up for labeling with different molecules.
- ⁇ f. bovis BCG bacilli were continuously cultured in the presence or absence of the above compounds at 37°C under 5% C0 2 .
- cultured bacilli were labeled with 1 ⁇ Ci per well (50 ⁇ l of 20 ⁇ Ci/ml solution) of 3 H-uracil (specific activity of 49 Ci/mmol, Amersham) , 3 H-methionine (specific activity of 197 mCi/mmol, DuPont NEN) , or 3 H-acetate (specific activity of 100 mCi/mol, DuPont NEN) .
- ⁇ f. bovis BCG in the labeled cultures were harvested onto glass fiber filters (Packard) using a Filtermate 196 harvester (Packard) . The filters were then washed six times with water and air dried. The radioactivity associated with each sample on filters was detected using a MatrixTM 96 Direct Beta Counter (Packard) .
- Homoserine reduces utilization of precursors for nucleic acid, protein, or lipid biosynthesis.
- the uptake of radiolabeled uracil has been used as a quantitative measure for estimating mycobacterial abundance (Flesch and Kaufmann, Infect. Immun., 56:1464-1469, 1988) .
- This technique was used to evaluate the effects of homoserine on ⁇ f. bovis BCG growth.
- ⁇ f. bovis BCG was labeled with 3 H-uracil in liquid culture medium containing various concentrations of D-homoserine or L-homoserine. As shown in Figure 4 A and B, while the amount of cell- associated uracil in untreated or D-homoserine treated ⁇ f.
- bovis BCG cultures increased continuously over a 7 day period, the ability of ⁇ f. bovis BCG to incorporate uracil was significantly inhibited by L- homoserine.
- the levels of inhibition by L-homoserine were similar to those obtained with 50 ⁇ g/ml D- cycloserine, a known mycobactericidal agent.
- L-homoserine treated ⁇ f. bovis BCG was also evaluated for specific reductions in lipid or protein biosynthesis by monitoring the incorporation of 3 H-acetate and 3 H-methionine, respectively.
- treatment with L-homoserine drastically reduced the incorporation of both 3 H- acetate and 3 H-methionine.
- L-homoserine appears to have global effects on M. bovis BCG metabolism in vitro, and these incorporation studies have not demonstrated specific reductions in nucleic acid, lipid, or protein biosynthesis by treatment with this compound.
- Viability was evaluated in agar culture.
- ⁇ f. bovis BCG approximately IO 6 cfu/ml
- ⁇ f. bovis BCG approximately IO 6 cfu/ml
- ⁇ f. bovis BCG approximately IO 6 cfu/ml
- bovis BCG in the starting culture This level of recovery was similar to that observed for ⁇ f. bovis BCG culture treated with 10 ⁇ g/ml of ethambutol (at least 2.5-fold above MIC) and was about 10 times higher than the live ⁇ f. bovis BCG present in the culture treated with 0.1 ⁇ g/ml of isoniazid (at least 4-fold above MIC) .
- the inhibitory effect of L-homoserine on ⁇ f. bovis BCG growth is more like the bacteriostatic effect of ethambutol.
- ⁇ f. bovis BCG One milliliter portions of the ⁇ f. bovis BCG suspension were transferred to 1.5 ml microfuge tubes and cultured in the presence of PBS or 200 ⁇ g/ml of D-homoserine, L-homoserine, or L-homoserine lactone at 37°C with shaking for 2 hr.
- ⁇ f. bovis BCG were then labeled with 10 ⁇ l of 3 H-glutamic acid (specific activity of 50 mCi/mmol, Amersham) . After 30 min incubation the glutamate uptake reaction was terminated by immediately chilling the reaction tubes on ice.
- L- homoserine partially blocks glutamate uptake in both drug sensitive and drug resistant strains. Moreover, the concentrations of L-homoserine at which glutamate transport was inhibited were higher (200 ⁇ g/ml) than the MIC of L-homoserine for sensitive ⁇ f. bovis BCG (25-50 ⁇ g/ml) . These observations indicate that the inhibitory effect of L-homoserine on glutamate transport cannot completely account for the inhibitory effect of L-homoserine on growth in ⁇ f. bovis BCG.
- the human macrophage cell line U937 (ATCC CRL 1593; Sundstrom and Nilsson, Intl. J. Cancer, 17:565-577, 1976) , was used for the toxicity assay.
- U937 cells human promonocytic cell line
- 5 x IO 4 cells per well were treated with L-homoserine lactone at a concentration of 0, 7.5, 15, 30, 60, 120, 240, or 480 ⁇ g/ml in 96-well plates.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
A method for inhibiting growth of slow growing mycobacteria involves administering an inhibitory amount of L-homoserine, L-homoserine lactone or a precursor thereof to mycobacteria. This method can be used to detect the presence of slow growing mycobacteria and to treat patients infected with M. tuberculosis.
Description
L-HOMOSERINE AND L-HOMOSERINE LACTONE AS BACTERIOSTATIC AGENTS FOR M. TUBERCULOSIS AND M. BOVIS
BACKGROUND OF THE INVENTION Several mycobacteria are important human pathogens and establish persistent infections. M. tuberculosis and M. bσvis are two species of mycobacteria that cause tuberculosis . M. tuberculosis is resistant to the enzyme activities of neutrophils and/or macrophages. As a result, M. tuberculosis survives, continuing to grow and later to cause infection because of the failure of these phagocytic cells to kill the invading pathogens. Treatment of tuberculosis is based upon intensive and prolonged exposure of the organisms to bacterial antagonists such as antibiotics. However, drug resistance is a significant problem. Drug resistance in tuberculosis is time consuming to diagnose and is a leading cause of morbidity from the infection. In New York, the incidence of multidrug resistant tuberculosis (MDRTB) reached 30% in 1991 (Frieden et al . , N. Eng. J. Med., 328:521- 526, 1993) . About 80% of MDRTB cases occur in HIV- infected individuals, and the combination of HIV and MDRTB has been reported to carry a mortality of 70- 89% (Fischl et al . , Ann. Intern. Med., 117:177-183, 1992; Fischl et al . , Ann. Intern. Med., 117:184-190, 1992; Dooley et al . , Ann. Intern. Med., 117:257-259, 1992) . The last new drug for tuberculosis, rifampin, was introduced in 1967 (Wolinsky, In: Gorbach et al., eds. Jπfecϋious Diseases . .B. Saunders, Philadelphia, pp. 313-319, 1994) . In spite of the numerous unique aspects of mycobacterial cellular physiology which might provide novel drug targets,
only recently has interest been renewed in identifying such targets.
The only absolute proof of active tuberculosis disease is the culture and identification of M. tuberculosis from tissue or body fluid (see for example, the description in U.S. Pat. No. 5,582,985). Most clinical mycobacteriology laboratories currently use radio etric liquid culture systems (e.g., the Bactec 460 TB machine, Becton-Dickinson, Sparks, MD) in combination with DNA probes (e.g., AccuProbe Kit, Gen-Probe, Inc., San Diego, CA) for species identification. Radiometric detection with liquid culture yields positive cultures in an average of 10-15 days. However, after acid-fast bacilli (AFB) are detected, there is a waiting period of 3-6 days before enough bacilli have grown to perform the DNA probe analysis for species identification (Miller et al. , J. Clin. Microbiol., 32:393-397, 1994). Hence the entire process requires 14-21 days to complete (Heifets et al . , In: Bloom B.R., ed. Tuberculosis : Pa thogenesis , Protection and Control , ASM Press, Washington, DC, pp. 85-110, 1994) .
DNA probe hybridization is the current state- of-the-art technology for species identification once an isolate has been grown up in the standard cultivation medium. The DNA probe test is expensive, difficult to perform in developing countries, and requires an additional day of testing beyond the 3-6 additional days required to grow the isolate to sufficient levels. There is a need in the art to develop new drugs to treat tuberculosis, especially that caused by multidrug resistant M. tuberculosis . There is also a need in the art to develop new
diagnostic tests to achieve identification inexpensively, simply, and without the need for 4-7 additional days of testing.
SUMMARY OF THE INVENTION It is an object of the invention to provide methods for inhibiting growth of slow growing mycobacteria.
It is yet another object of the invention to provide methods for identifying slow growing mycobacteria.
These and other objects of the invention are provided by one or more of the embodiments described below. In one embodiment of the invention there is provided a method for inhibiting growth of slow growing mycobacteria which comprises administering to said mycobacteria an inhibiting amount of L- homoserine, L-homoserine lactone or a precursor thereof.
A method for identifying slow growing mycobacteria is provided by this invention. The method comprises inoculating a clinical specimen into a cultivation medium in the presence of and in the absence of L-homoserine, L-homoserine lactone or a precursor thereof. If the specimen grows in the cultivation medium in the absence of these compounds, but not in the medium which contains the compounds, the presence of a slow growing mycobacterium is indicated.
Preferred slow growing mycobacteria that are targets of the invention are tuberculous mycobacteria and non-tuberculous mycobacteria. Tuberculous mycobacteria include M. tuberculosis , M. bovis , M. africanuum, and M. micro ti ; non-
tuberculous mycobacteria include M. avium, M. intracellulare, M. kanβasii , and M. leprae . Because the compounds of the present invention act by a mechanism which is different from those characterized for known anti-mycobacterial agents, a combination of the different classes of anti-mycobacterial agents provides a composition useful for inhibiting growth of slow growing mycobacteria. A method for identifying targets of L- homoserine, L-homoserine lactone, or a precursor thereof that cause growth inhibition is provided by the invention.
The present invention provides the art with methods of using compounds which are specifically bacteriostatic for slow growing mycobacteria. This invention thus provides methods for identifying and treating tuberculosis, especially tuberculosis caused by multidrug resistant M. tuberculosis . This invention also provides an inexpensive, simple and quick diagnostic test which distinguishes slow growing mycobacteria, including M. tuberculosis complex organisms, from non-tuberculous, rapid growing mycobacteria in the clinical laboratory. Moreover, the invention provides a mycobacterial cell line resistant to growth inhibition by L- homoserine, L-homoserine lactone, or a precursor thereof useful as a control in the methods of the invention.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 illustrates the metabolic biosynthesis of homoserine, homoserine phosphate, and homoserine lactone. Enzymes that control each
step of the metabolic pathway are shown beneath the reaction arrows.
Figure 2 shows chemical compounds useful in understanding the present invention. Figure 3 shows growth-inhibited Λf. bovis BCG exposed to L-homoserine lactone are still metabolically active as measured by continued utilization of uracil. Panel A shows treatment with 50 μg/ml, panel B shows treatment with 100 μg/ml, and panel C shows treatment with 200 μg/ml for medium alone (square) , L-homoserine lactone (circle) , and L-homoserine (diamond) . The abscissa is time of treatment in days, and the ordinate is counts per 4 min. Figure 4 shows inhibition of Λf. bovis BCG growth by homoserine as determined by uracil, acetate, or methionine uptake. D-homoserine is shown in panels A, C and E at 50 μg/ml (diamond) or 200 μg/ml (circle) ; L-homoserine is shown in panels B, D and F at 50 μg/ml (diamond) or 200 μg/ml (circle) ; and controls are medium alone (square) and D- cycloserine at 50 μg/ml (triangle) . The abscissa is time in days, and the ordinate is counts per 4 min. Figure 5 shows survival of Λf. bovis BCG after homoserine or homoserine lactone treatment. From top to bottom: square represents phosphate-buffered saline, diamond represents D-homoserine, circle represents L-homoserine, triangle represents L- homoserine lactone, inverted triangle represents ethambutol, and asterisk represents isoniazid. The abscissa is time of treatment in days, and the ordinate is colony forming units per milliliter.
Figure 6 shows specific inhibition by L- homoserine of glutamate uptake in wild type Λf. bovis
BCG and L-homoserine resistant Λf. Jbovis BCG. Panel A illustrates glutamate uptake in wild type M. bovis BCG determined against increasing concentrations of L-homoserine (filled square) or D-homoserine (open square) . The dpms obtained from the experimental samples were normalized to controls. When the value was greater than a hundred, 100% was used. Panel B glutamate uptake in the presence of 200 μg/ml L- homoserine in wild type Λf. Jbovis BCG as well as two L-homoserine resistant Λf. Jbovis BCG strains. The error bar indicates the standard deviation for each strain tested.
DETAILED DESCRIPTION OF THE INVENTION It is a discovery of the present invention that L-homoserine and its metabolites can inhibit the growth of slow growing mycobacteria. In particular, these compounds are specifically bacteriostatic for slow growing mycobacteria including Λf. tuberculosis, multidrug resistant isolates of Λf. tuberculosis, and Λf. bovis . This discovery provides the basis for using these compounds therapeutically to alleviate clinical infections and diagnostically to identify whether a potentially pathogenic species is present. Compounds which may be used according to the present invention include homoserine, homoserine lactone, and precursors thereof. The precursors are compounds that can be converted to L-homoserine or L-homoserine lactone under the conditions known in the art (see Figure 1) . The precursors include L- homoserine phosphate.
The bacteria which are susceptible to growth inhibition by homoserine and its metabolites are
mycobacteria. Mycobacteria, are slender, straight or curved rods. They usually occur singly or in clusters but may occasionally exhibit a branching and filamentous form. Mycobacteria are well characterized in the art. They are usually acid fast and grow on ordinary medium known in the art. The time interval required for the cell to divide or for the population to double is known as the generation time. Not all bacteria have the same generation time; for some rapid growers, such as E. coli , it is 15 to 20 minutes; for others it is hours. Slow growing mycobacteria have a generation time of at least 10 hours; for Λf. tuberculosis, and for Λf. bovis the generation time is about 24 hours. In general, clinical rnycobacteriology laboratories cannot rely upon the time it takes for a body fluid specimen to grow a mycobacterial species to determine whether the species is a rapid grower or a slow grower, because the density of the inoculum is not known. For example, a heavily infected sputum containing slow growing M. tuberculosis might turn positive in 7 days, while a lightly colonized sputum containing rapid growing Λf. chelonae might turn positive in 12 days. Usually slow growing mycobacteria, e.g., Λf. tuberculosis, are sensitive to antimycobacterial drugs. However, a large variety of mycobacterial mutants have been isolated and have been the subject of intensive study. Mutation can, and often does, result in an increased tolerance to inhibitory agents, particularly antibiotics. In some cases, mycobacteria alter genetic determinants encoding enzymes involved in the mechanism of action of the antibiotic rendering the drug ineffective. Multidrug resistant Λf. tuberculosis are those
bacteria that have become resistant to two or more antibiotics either by mutation or by acquisition of drug resistance determinants.
Though not wishing to be limited to any technical explanation, applicant believes that compounds of the invention inhibit the growth of slow growing mycobacteria through an autoinducer mechanism. Therefore an autoinducer can also be contemplated in the present invention. An autoinducer is a small diffusible molecule which is produced and then secreted by a microorganism during metabolism and which then acts to increase or decrease the expression of the genes of the microorganism. Autoinducers may be synthesized by adding a fatty acid chain to a L- homoserine lactone (Figure 2) . L-homoserine lactone is widespread in bacteria. Known autoinducers include L-homoserine lactone derivatives or modified L-homoserine lactones including N-acyl-L-homoserine lactones such as N- (3-oxohexanoy1) -L-homoserine lactone, N- (3 -hydroxybutanoyl) -L-homoserine lactone, N- (3 -oxododecanoyl) -L-homoserine lactone, N- (3- oxooctanoyl) -L-homoserine lactone, N-butanoyl-L- homoserine lactone, and N-hexanoyl-L-homoserine lactone. PCT Publication WO 92/18614 describes various members of this family of compounds, including optically active isomers thereof. Precursors of autoinducers can be used by the enzymes of a microorganism to produce autoinducers . Bacteria use autoinducers to communicate intercellularly. These autoinducers function as quorum sensors in certain bacteria and, when present at sufficient concentrations, activate regulatory cascades leading to the transcription of genes
associated with high density growth. The first antoinducer reported was N- (3-oxohexanoyl) homoserine lactone (OHHL) from the marine symbiont bacterium Photobacterium (previously Vibrio) fischeri (Eberhard et al., Biochemistry, 20:2444- 2449, 1981) . P. fischeri grows to densities of IO11 cfu/ml within the light organs of certain marine fish and squids. At these high densities, OHHL produced by the organism reaches a critical concentration which leads to the activation of bioluminescence genes and light production (Eberhard, J. Bacteriol., 109:1101-1105, 1972; Kaplan and Greenberg, J. Bacteriol., 163:1210-1214, 1985) . But when P. fischeri lives as a free organism in sea water at low density (about IO2 cfu/ml) , the bacterium is not bioluminescent . Thus, the autoinduction system allows P. fischeri to discriminate between high-density and low-density environments, and to modulate bioluminescence accordingly.
The molecular genetics of autoinducer biosynthesis and subsequent gene activation in P. fischeri is controlled by luxl and luxR genes. The gene product of luxl is responsible for the synthesis of OHHL and LuxR is the receptor for the autoinducer. Once the autoinducer is bound, LuxR becomes a transcriptional activator that activates genes involved in bioluminescence production (Fuqua et al., J. Bacteriol., 176:269-275, 1994) . Similar autoinduction systems that are controlled by luxl/luxR homologs have been identified from other species including Pseudomonas aeruginosa , Agrobacterium tu afaciens, Erwinia carotovora, Streptomyces and others. Although the phenotypes
which the autoinducers activate may differ among species, the common theme for autoinduction is density-dependent gene activation. For example, in the opportunistic pathogen P. aeruginosa, lasl and lasR, which are the homologs of luxl and luxR, respectively, regulate the production of exoenzymes which are important virulence factors (Gambello et al., J. Bacteriol., 173:3000-3009, 1991; Gambello et al., Infect. Immun., 61:1180-1184, 1993; Passador et al., Science, 260:1127-1130, 1993; Toder et al. , Infect. Immun., 64:2062-2069, 1991) .
The autoinducers produced by different bacteria are species-specific. Gram-positive bacterium Strepto yces spp . produce butyrolactones rather than homoserine lactones as their autoinducers (Horinouchi and Beppu, Annu. Rev. Microbiol., 46:377-398, 1992) . Increasing concentrations of A-factor, a butyrolactone derivative (Figure 2) , in stationary phase trigger morphological and biochemical changes in S . griseus leading to sporolation and the production of streptomycin (Horinouchi et al. , J. Bacteriol., 171:1206-1210, 1989; Beppu, Gene, 115:159-165, 1992) . In addition to intercellular signaling with
N-acyl-L-homoserine lactones or butyrolactones, other bacteria such as Escherichia coli are believed to use non-acylated L-homoserine lactone itself as an intracellular signaling molecule. In E. coli L- homoserine lactone accumulates in stationary phase and is believed to stimulate the production of RpoS, a major regulatory protein for stationary phase survival. L-homoserine is the intermediate in the biosynthesis of methionine, threonine, and
isoleucine from aspartate, and homoserine lactone is the byproduct of the synthetic pathway (Figure 1) . According to a model proposed by Huis an and Kolter (Science, 265:537-539, 1994), L-homoserine lactone could accumulate intracellularly in response to early amino acid deficiencies and thus provide an early warning signal for impending starvation.
Given the fact that autoinduction systems signaled by homoserine lactone or butyrolactone-like inducers are common sensors for population control among diverse species of bacteria, the effects of exogenous homoserine on the proliferation of slow growing mycobacteria was studied. L-homoserine inhibits growth of Mycobacterium smegmatis - a non- pathogenic rapid grower; the mechanism for growth inhibition is thought to be a blockade in glutamate uptake by L-homoserine (Sritharan et al. , J. Gen. Microbiol., 133:2781-2785, 1987) . L-homoserine is also toxic for slow growing mycobacteria in culture by a bacteriostatic mechanism. However, its effect on glutamate uptake in Λf. bovis BCG cannot account for the growth inhibition observed.
In one embodiment, the invention compounds are employed to inhibit the growth of slow growing mycobacteria including Λf. Jbovis, M. tuberculosis, and multidrug resistant Λf. tuberculosis . A mammal infected with slow growing mycobacteria can be treated with an effective amount of L-homoserine, L- homoserine lactone or a precursor thereof. In a preferred embodiment an effective amount of these compounds is administered to a human infected with Λf. tuberculosis, Λf. bovis or multidrug resistant isolates of Λf. tuberculosis. This treatment kills or inhibits the growth of Λf. tuberculosis, M. bovis or
multidrug resistant Λf. tuberculosis. Other slow growing mycobacteria that may be affected by L- homoserine, L-homoserine lactone or a precursor thereof are described by Peterson (In: Rossman, M.D. and MacGregor, R.R., eds. Tuberculosis, Clini cal Management and New Challenges . McGraw-Hill, New York, pp. 359-372, 1995) .
The invention may also be effective in treating disease caused by rapid growing non- tuberculous mycobactaria such as, for example, Λf. fortuiturn, Λf. chelonae, M. abscessus, Λf. peregrinum, and Λf. marinum (Wright and Wallance, In: Rossman, M.D. and MacGregor, R.R., eds. Tuberculosis, Clinical Management and New Challenges . McGraw-Hill, New York, pp. 373-389, 1995) by killing or inhibiting the growth of the relevant pathogen.
In some of the examples below, Λf. bovis BCG is sometimes used to demonstrate the invention because this mycobacteria is an art-recognized model for the human pathogen Λf. tuberculosis (Jacobs and Bloom, In: Bloom B.R., ed. Tuberculosis : Pathogenesis, Protection and Control , ASM Press, Washington, DC, pp. 253-268, 1994) .
The compounds are preferably formulated prior to administration. Suitable pharmaceutical formulations are prepared by known procedures using well known and readily available ingredients (see Martin, E.W., Remington's Pharmaceutical Sciences , Mack Publishing, Easton, PA) . The formulations include those suitable for oral, parenteral
(including subcutaneous, intradermal, intramuscular, intravenous, intrathecal, and intra-articular) and topical (including dermal, sublingual and intrabronchial) administration although the most
suitable route may depend upon, for example, the condition of the recipient. The formulation may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired form.
Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets, or tablets, each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid emulsion or a water-in-oil liquid emulsion. A preferred delivery vehicle for the treatment of intracellular infection is a liposome such as described in, for example, U.S. Pat. Nos. 5,000,958 and 5,270,052) . The active ingredient may also be presented as a bolus, electuary, or paste.
Formulations for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats, and solutes which render the formulation isotonic with the blood of the intended recipient. Aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents may also be added.
Formulations for topical administration in the mouth, for example buccally or sublingually, include lozenges comprising the active ingredient in a flavored bases such as sucrose and acacia or
tragacanth, and pastilles comprising the active ingredient in a bases such as gelatin and glycerin, or sucrose and acacia. It should be understood that in addition to the ingredients particularly mentioned above, the formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question.
The compounds of the invention may be administered orally or via injection at a dose of from about 2.5 mg/Kg body weight per day to about 2 g/Kg body weight per day. More preferably the dose would be about 25 mg/Kg body weight per day to about 200 mg/Kg body weight per day. The dose range for adult humans is generally from about 50 mg to about 300 g/day. One skilled in the art will recognize that the amount sufficient to inhibit the growth of slow growing mycobacteria varies depending upon an affected tissue size, age and body weight of the patient, and concentration of the compound in the formulation. Generally, the precise amount of compound to be administered as a therapeutic agent (e.g., amount in a dose, number of doses, timing of doses) will be determined on a case-by-case basis at the discretion of the attending physician. The extent of the mycobacterial infection, body weight, and age of the patient are also considerations. Clinical specimens can be tested for the presence of slow growing mycobacteria including Λf. tuberculosis according to this invention. The clinical specimens can include samples obtained from biopsies, blood, and body discharge such as sputum, peritoneal fluid, pleural fluid, gastric content, spinal fluid, urine, and the like. Clinical
specimens can be inoculated into a cultivation medium. If the mycobacteria isolate grows in standard cultivation medium but not in cultivation medium when it contains L-homoserine, L-homoserine lactone or precursors thereof, the presence of a slow growing mycobacterium is indicated and the presence of a rapid growing mycobacterium such as Λf. smegmatis or M. vaccae is eliminated.
In a cultivation medium, the minimal inhibitory concentrations of L-homoserine or L- homoserine lactone for susceptible bacteria generally will range from about 22 to about 45 μg/ml in liquid cultivation medium and from about 25 to about 50 μg/ml in solid cultivation medium. Resistant bacteria grow well at concentrations of L- homoserine and L-homoserine lactone in excess of about 200 μg/ml. To achieve differential inhibition, the preferred concentration of the added compound in the cultivation medium is from about 100 μg/ml to about 200 μg/ml for either L-homoserine or L- homoserine lactone. The composition and the preparation of liquid and solid cultivation medium for mycobacteria are well known in the art and are commercially available. See chapter 7 "Current Laboratory Methods for the Diagnosis of
Tuberculosis" In: Bloom, B.R. ed. Tuberculosis : Pathogenesis, Protection and Control , ASM Press, Washington, DC, 1994 for a detailed description. The solid media can be, but is not limited to, egg-based media (Lowenstein-Jensen Ogawa, and American Trudeau Society) and agar-based media (Middlebrook-Cohn 7H10 agar and 7H11 agar) . The liquid media can be, but is not limited to, Middlebrook 7H12 broth and 7H9 broth. Slow growing mycobacteria usually grow at
37°C and pH between about 5.8 to about 8.0. The cultivation medium desirably contains some incorporated antibiotics which inhibit the growth of the non-mycobacterial contaminants. The composition of the cultivation medium can affect the minimal inhibitory concentration.
Animal cells in culture or bacterial cells in culture are examples of samples that may be screened for mycobacteria. Cell and tissue cultures are terms of art that refer to propagation in vitro of isolated animal cells, while bacterial culture refers to propagating bacteria in a liquid or solid medium in the presence or absence of host cells in vitro. Preferred host cells include mycobacterium- infectable cells, in particular cells of the macrophage-phagocyte lineage. Such mycobacterium- infectable cells may be identified by exposing the putative mycobacterium-infectable cell to mycobacteria, and then utilizing the methods described in this application to detect the presence of intracellular mycobacteria or their growth. Such cell lines are publicly available from the American Type Culture Collection (ATCC) and the NIGMS Human Genetic Mutant Cell Repository. In another embodiment, the homoserine related compounds are employed to inhibit the growth of mycobacteria in infected macrophages, monocytes, histiocytes, Kupffer cells and microglia. These cells may be isolated from a human and cultured in vitro; in particular, alveolar macrophages may be obtained from bronchoalveolar lavage or peripheral blood macrophages .
Screening for other useful agents (e.g., an antibiotic known to the art, such as described in,
for example, U.S. Pat. Nos. 5,000,958 and 5,270,052) that have a therapeutic effect in combination with the invention compounds (preferably the effect is synergistic because separate and distinct aspects of mycobacterial metabolism are targeted) , or for designing improved derivatives of the compounds which maximize activity and penetrability into human cells and/or minimize toxicity and side effects (e.g., acylated derivatives of L-homoserine lactone) are further embodiments of the invention. In a particularly preferred embodiment L-homoserine lactone can be added in a concentration of up to about 200 μg/ml to a human macrophage cell line infected with slow growing mycobacteria without toxic effect on the macrophage cells.
A mycobacterial gene or genetic program, as well as proteins encoded by such genes, may be regulated by homoserine or homoserine lactone. Mycobaterial cultures may be compared prior to and after treatment with homoserine or homoserine lactone. For example, if homoserine acted as an autoinducer in mycobacteria, gene transcription may be induced or repressed by addition of homoserine to the culture. Homoserine regulated genes may be identified by screening a subtractive cDNA library, or by differential screening of cDNA or genomic clone libraries of mycobacteria. Such regulated transcripts will be translated into regulated proteins, such proteins may be identified by comparing the pattern of proteins expressed prior to and after treatment with homoserine or homoserine lactone. For example, pre- and post-treatment cultures of mycobacteria may be pulsed with 35S-amino acids, protein extracts may be made from whole cell
lysates or subcellular fractions, and regulated proteins may be identified by their increased or decreased signal intensity in two-dimensional gels 35S-labeled proteins from pre- and post-treatment cultures. Proteins of interest (i.e., labeled proteins which increase or decrease in abundance) may be isolated, N-terminal or internal peptide amino acid sequence may be determined, and the regulated gene of interest identified. Homoserine or homoserine lactone regulated genes may also be identified by promoter trapping. A clone library of mycobacterial genomic DNA fragment inserted into a promoter probe vector (the general strategy is described in U.S. Pat. No. 4,725,535) can be constructed to operably linked the DNA fragment with an indicator gene (e.g., lacZ, luxAB, xylE, firefly luciferase, the gene for green fluorescent protein or gfp, melC) , such that a promoter contained in the DNA fragment may direct the transcription of the indicator gene. A suitable indicator gene will be transcribed and produce a detectable indicator product under appropriate assay conditions. Individual clones of the library may be introduced into Λf. tuberculosis or the host cell, and colonies replica plated under conditions either having or lacking homoserine or homoserine lactone. DNA fragments will be isolated form colonies which produce indicator product only when homoserine or homoserine lactone is present because they could contain homoserine-dependent promoters.
Alternatively, a construct containing the indicator gene but no operably linked promoter may be randomly integrated into the mycobacterial chromosome. Clones which contain integrations near homoserine-regulated
promoters may be identified after addition of homoserine by screening for the indicator product . Those integrations could mark the sites of homoserine-regulated promoters and isolating the mycobacterial genes associated with such promoters may also identify homoserine-regulated genes.
All books, articles, and patents cited in this specification are incorporated herein by reference in their entirety. In particular, the present invention was disclosed in U.S. Provisional Appln. No. 60/010,996, filed February 1, 1996, the entire contents of which are hereby incorporated by reference and relied upon.
The following examples are provided for illustrative purposes only and are not intended to limit the scope of the invention.
EXAMPLES The strains of mycobacteria used were the Λf. bovis BCG (Pasteur strain, ATCC #5734) , Λf. tuberculosis H37Rv (ATCC 27294) , D-CSR (ATCC 35826) , Λf. smegmatis mc26 1-2C, a transformable variant of mc26 (Zhang et al . , Mol. Microbiol., 5:381-391, 1991) , and the A4 strain of Λf. avium (Cooksey et al . , Antimicrob. Agents Chemother., 39:754-756, 1995) . Λf. tuberculosis clinical isolates were obtained from Loayza Hospital (Lima, Peru) . All mycobacterial strains were cultured in Middlebrook 7H9 broth or 7H10 agar (Difco) supplemented with 10% ADC (albumin dextrose complex) , 50 μg/ml cycloheximide (Sigma), 0.2% glycerol and 0.05% Tween 80 (7H9 broth only) . Nitrogen-depleted 7H9 medium was prepared by omitting monosodium glutamate and ammonium sulfate from the original formulation.
Example 1 :
The BACTEC procedure for drug susceptibility testing of mycobacteria is based on the same principle employed in the conventional (agar) method except that a liquid medium is used. Instead of counting colonies, the growth is monitored radiometrically. Resistance is determined by comparing the rate of growth in the control and the vials containing test drug. When an antituberculous drug is added to the medium, suppression can be detected by a reduced daily growth index (GI) when compared to the control (Siddiqi, "Radiometric (BACTEC) tests for slowly growing mycobacteria." In: Isenberg, H.D. ed. Clinical Microbiology Procedures Handbook, Vol. 1. ASM Press, Washington, DC, 1992) . Unlike conventional methods (agar dilution) which require 3 weeks, the BACTEC method results are usually reportable within 4 to 5 days. The growth of Λf. bovis BCG, Pasteur strain, ATCC 35734, Λf. tb. H37Rv, ATCC 25618, Λf. tb. JHH strain 9453 (a multidrug resistant strain resistant to isoniazid at 0.1 μg/ml, resistant to rifampin at 1.0 μg/ml, resistant to ethambutol at 2.5 μg/ml, and resistant to streptomycin at 2.0 μg/ml) , Λf. smegππatis and Λf. vaccae was tested.
Inoculum from growth on solid medium such as Middlebrook 7H10/7H11 or LJ slants was added to 2 ml of the special diluting fluid (Siddiqi, "Radiometric (BACTEC) tests for slowly growing mycobacteria." In: Isenberg, H.D. ed. Clinical Microbiology Procedures Handbook, Vol. 1. ASM Press, Washington, DC, 1992) containing glass beads. Then, the special diluting fluid was vortexed until the suspension is well dispersed with as few clumps as possible. The
suspension was showed to stand for at least 30 minutes to allow mycobacterial clumps to settle. Then the homogeneous supernatant was transferred to a sterile tube and the turbidity was adjusted to match a 0.5 McFarland standard. One-tenth ml of the inoculum prepared in this manner was added to Bactec 12B culture bottles (Becton Dickinson, Sparks, MD) containing L-homoserine or L-homoserine lactone at various concentrations ranging from 0 to 180 μg/ml. Growth index (GI) values were measured at 24 hour intervals using a Bactec 460 TB radiometric growth detection machine (Becton Dickinson, Sparks, MD) . The difference in the GI values from the previous day is designated as ΔGI. Negative or zero ΔGI values indicate no growth, while positive ΔGI values indicate an increase in growth. An isolate was determined to be susceptible to a particular concentration of L-homoserine or L-homoserine lactone if the ΔGI for the test sample was less than the ΔGI for the untreated (drug concentration = 0) control, provided that the untreated control reached an absolute GI of 30 or more. If the ΔGI for the test sample exceeds or is similar to that for the untreated control, the isolate was resistant to that particular concentration of L-homoserine or L- homoserine lactone. It was shown that L-homoserine lactone inhibited the growth of Λf. bovis BCG, Pasteur strain, ATCC 35734, Λf. tb. H37Rv, ATCC 25618, Λf. tb. JHH strain 9453, resistant to INH, RIF, EMB, STR, with a minimum inhibitory concentration (MIC) of 22-45 μg/ml. In contrast, they have no effect upon Λf. smegπiatis and Λf. vaccae with the MIC being higher than 200 μg/ml.
Similar results have been obtained for L- homoserine lactone with Λf. bovis BCG and Λf. smegmatis using the agar dilution method (Kent and Kubica, Public Heal th Mycobacteriology : A Guide for the Level III Laboratory. U.S. Dept. of Health and Human Services, Atlanta, GA, 1985) . Cultures of Λf. bovis BCG or Λf. smegmatis grown in 7H9 supplemented with ADC (Kent and Kubica, ibid.) and cycloheximide (50 μg/ml) were first adjusted to a McFarland standard of 1, and then diluted to IO"2 and 10"" for Λf. bovis BCG or 10"3 and IO"5 for Λf. smegma tis . Quadrant plates prepared with 7H10 medium containing different concentrations of homoserine lactone were inoculated with diluted suspensions, 0.1 ml per each quadrant and one suspension per plate. One of the four quadrants in each plate functions as control medium without L-homoserine lactone. The inoculum was spread evenly in each quadrant using a sterile loop. The plates were air-dried and incubated at 37°C for 3 weeks for Λf. bovis BCG, Λf. avium, or Λf. tuberculosis strains; or 5 days for Λf. smegmatis . For Λf. bovis BCG, colonies were observed in the quadrants with 0 or 25 μg/ml L-homoserine lactone, but not in the quadrants with 50 or 100 μg/ml L- homoserine lactone; whereas, for Λf. smegmatis was observed in the quadrants with L-homoserine up to 200 μg/ml.
To determine how susceptible various mycobacteria are to homoserine and homoserine lactone, several commonly used laboratory strains were selected including rapid and slow growers, and pathogenic and nonpathogenic mycobacteria. Using the agar dilution method these mycobacteria were tested against various concentrations of D-homoserine, L-
homoserine, and L-homoserine lactone. The minimal inhibitory concentration (MIC) is the concentration which inhibited the bacterial colony forming units by more than 75% compared to the controls. The MIC for each strain of mycobacteria used are listed in Table 1. Λf. bovis BCG was susceptible to L- homoserine and L-homoserine lactone with MIC varying between 25-50 μg/ml. D-homoserine had little effect on Λf. bovis BCG growth on 7H10 agar plates, indicating that only the L-isomer is active as a growth inhibitor. Λf. avium, another slow growing mycobacterium which is the opportunistic pathogen in immunocompromised individuals, was also sensitive to 50 μg/ml of L-homoserine and L-homoserine lactone. In contrast, the rapid growing nonpathogenic mycobacterium. Λf. smegmatis, was resistant to L- homoserine and L-homoserine lactone. A commonly used laboratory strain of M. tuberculosis, H37Rv, although it is slow growing and pathogenic, was able to grow in the presence of 100 μg/ml of L-homoserine and L-homoserine lactone. Since H37Rv has been adapted in laboratories for almost a century, it may differ from clinical isolates of Λf. tuberculosis in terms of its physiological behavior.
Table 1: Susceptibility of mycobacteria to homoserine (HS) , homoserine lactone (HSL) , or cycloserine (CS) . a determined by dilution in agar culture. b ND = not done.
Table 1
MIC (μg/ml )
D-HS L-HS L-HSL D-CS
M. bovis BCG >200 25-50 25-50 40
M. smegmatis mc26 1-2C >200 >200 >200 NDb
M. avium >200 50 50 <12.5
M. tuberculosis H37Rv >100 >100 >100 25
| M. tuberculosis D-CSR >100 >100 >100 50
J M. bovis BCG HSR 1 >200 >100 >100 40 |
In view of the somewhat similar chemical structure of homoserine lactone and cycloserine (see Figure 2) , it was important to address whether L- ho oserine or L-homoserine lactone might mimic D- cycloserine to act as an inhibitor of peptidoglycan biosynthesis (see U.S. Pat. No. 5,260,324 for a discussion of unwanted side-effects associated with cycloserine treatment) . To address this question, the MIC to D-cycloserine, a second line anti- mycobacterial agent, was determined for several slow growing mycobacteria including a D-cycloserine resistant H37Rv strain and an L-homoserine resistant Λf. bovis BCG. As shown in Table 1, Λf. bovis BCG-HSR 1 was sensitive to D-cycloserine with the same MIC value of 40 μg/ml as its parental Λf. bovis BCG strain, indicating there is no cross resistance between L-homoserine and D-cycloserine. This observation implies that the mechanism of growth inhibition by L-homoserine against slow growing mycobacteria differs from the mechanism of action of D-cycloserine.
To evaluate the activity of L-homoserine and L-homoserine lactone in recent clinical isolates of Λf. tuberculosis, susceptibility of eight strains collected in 1995 in Lima, Peru was determined. As seen in Table 2, there is a spectrum of susceptibility levels to the L-homoserine in these clinical isolates. Four of them had an MIC of 50 μg/ml, two were very sensitive to L-homoserine with an MIC less than 25 μg/ml, and two were resistant to 100 μg/ml of L-homoserine. The sensitivity of these isolates to L-homoserine was independent of their susceptibility profiles to other commonly used anti- mycobacterial agents. For example, strain TBL002EP2
was susceptible to all five antibiotics tested but was relatively resistant to L-homoserine; whereas TBL019EP21, an MDR isolate, was susceptible to 50 μg/ml of L-homoserine. Our results suggest that sensitivity to L-homoserine varies among Λf. tuberculosis strains.
Table 2: Susceptibility of clinical isolates of M. tuberculosis to L-homoserine (L-HS) , isoniazid (INH) , streptomycin (SM) , ethambutol (EMB) , rifampin (RA) , and pyrazinamide (PZA) . a determined by dilution in agar culture. b determined by BATEC at the University Hospital (Albuquerque, NM) . c resistant to low concentration of SM (2 μg/ml) . d border level resistance.
Table 2 MIC (μg/ml) Susceptibility to common anti- mycobacterial drugs5
Example 2 :
A 3H-uracil incorporation assay was used to monitor the viability of Λf. bovis BCG exposed to different concentrations of L-homoserine lactone. Log-phase growing Λf. bovis BCG in 7H9 (OD600 = 0.5 to 0.6) was transferred to 24-well tissue culture plate, 1 ml per well. Homoserine lactone was added to final concentrations of 50, 100, and 200 μg/ml. The cultures were incubated at 37°C in 5% C02 for 7 days. On each day after homoserine lactone treatment, aliquots of 5 μl were removed from each well in triplicate and transferred to wells in a 96- well plate containing 195 μl 7H9 medium. The suspensions were then mixed with 50 μl of 7H9 medium containing 3H-uracil (20 μCi/ml) . After 6 hours labeling at 37°C in 5% C02, the bacilli were harvested onto a glass fiber filter, which was then washed with water, air-dried, and radioactivity on the filter was detected with an automatic scintillation counter. It is clear that Λf. bovis BCG treated with 50 μg/ml of L-homoserine lactone (a dose known to inhibit growth) continue to utilize uracil and hence are metabolically active (Figure 3) . These results show that L-homoserine lactone is bacteriostatic rather than bacteriocidal.
Example 3 :
Uracil, methionine, and acetate uptake was measured with homoserine treated Λf. bovis BCG. Dispersed Λf. bovis BCG suspensions in 7H9 with an optical density of 1 McFarland standard
(approximately IO8 bacilli) were diluted to IO"2, and 0.2 ml of each suspension were aliquoted in 96-well plates. Stock solutions of D-homoserine, L-
homoserine, or D-cycloserine (10 mg/ml prepared in PBS) were added to the Λf. bovis BCG cultures and the final concentrations of these compounds were 25, 50, 100 and 200 μg/ml. Control cultures were treated with PBS only. Multiple samples were set up for labeling with different molecules. Λf. bovis BCG bacilli were continuously cultured in the presence or absence of the above compounds at 37°C under 5% C02. At various time points, cultured bacilli were labeled with 1 μCi per well (50 μl of 20 μCi/ml solution) of 3H-uracil (specific activity of 49 Ci/mmol, Amersham) , 3H-methionine (specific activity of 197 mCi/mmol, DuPont NEN) , or 3H-acetate (specific activity of 100 mCi/mol, DuPont NEN) . After a 6 hr incubation, Λf. bovis BCG in the labeled cultures were harvested onto glass fiber filters (Packard) using a Filtermate 196 harvester (Packard) . The filters were then washed six times with water and air dried. The radioactivity associated with each sample on filters was detected using a Matrix™ 96 Direct Beta Counter (Packard) .
Homoserine reduces utilization of precursors for nucleic acid, protein, or lipid biosynthesis. The uptake of radiolabeled uracil has been used as a quantitative measure for estimating mycobacterial abundance (Flesch and Kaufmann, Infect. Immun., 56:1464-1469, 1988) . This technique was used to evaluate the effects of homoserine on Λf. bovis BCG growth. Λf. bovis BCG was labeled with 3H-uracil in liquid culture medium containing various concentrations of D-homoserine or L-homoserine. As shown in Figure 4 A and B, while the amount of cell- associated uracil in untreated or D-homoserine treated Λf. bovis BCG cultures increased continuously
over a 7 day period, the ability of Λf. bovis BCG to incorporate uracil was significantly inhibited by L- homoserine. The levels of inhibition by L-homoserine were similar to those obtained with 50 μg/ml D- cycloserine, a known mycobactericidal agent.
L-homoserine treated Λf. bovis BCG was also evaluated for specific reductions in lipid or protein biosynthesis by monitoring the incorporation of 3H-acetate and 3H-methionine, respectively. As shown in Figure 4 C-F, treatment with L-homoserine drastically reduced the incorporation of both 3H- acetate and 3H-methionine. Thus, L-homoserine appears to have global effects on M. bovis BCG metabolism in vitro, and these incorporation studies have not demonstrated specific reductions in nucleic acid, lipid, or protein biosynthesis by treatment with this compound.
The uptake studies also showed that D- homoserine was able to reduce the amount of uracil, acetate, and methionine taken up by Λf. bovis BCG as compared to untreated controls (Figure 4 A, C and E) . However, D-homoserine was considerably less effective in blocking uptake than L-homoserine (Figure 4 B, D and F) , as the levels of cell- associated radioactivities were gradually increasing over the 7 day period in the D-homoserine treated cultures whereas no increases were detected in the L-homoserine treated cultures.
Example : To determine whether the effect of L- homoserine lactone on Λf. bovis BCG growth is bactericidal or bacteriostatic, after Λf. bovis BCG was treated with homoserine lactone for 7 days, the
cultures were diluted 1000-fold in homoserine lactone-free 7H9 medium. Two hundred μl of each dilution were pipetted, in triplicate, into a 96- well plate (a total of three plates were prepared) . One plate was labeled immediately with 3H-uracil as described above, which gives the basal level of transcription after homoserine lactone treatment. The other two plates were labeled with 3H-uracil for a one or two week incubation, at 37°C and 5% C02. The amount of radioactivity incorporated by bacteria grown in these plates was compared to the basal level before homoserine lactone treatment . These results demonstrated that 3H-uracil utilization resumes after L-homoserine lactone treatment; the nature of inhibition is also examined in Example 5 and Figure 5.
Example 5:
Viability was evaluated in agar culture. To determine whether L-homoserine is bactericidal or bacteriostatic, Λf. bovis BCG (approximately IO6 cfu/ml) in 2 ml cultures was first treated with 200 μg/ml of D-homoserine, L-homoserine, or L-homoserine lactone; 0.1 μg/ml of isoniazid (bactericidal) ; 10 μg/ml of ethambutol (bacteriostatic) ; or with PBS (untreated control) in a 94-well plate at 37°C and 5% C02 for five days. Bacilli in each culture were then resuspended in fresh medium, and 0.1 ml of undiluted or diluted suspensions were inoculated onto antibiotic-free Middlebrook 7H 10 agar plates. The number of colonies on each plate were counted after 3 weeks incubation at 37°C in a humidified 5% C02 incubator. The colony forming units (cfu) of the initial Λf. bovis BCG culture were determined by
plating a series of dilutions of this culture onto 7H10 agar plates in duplicate. The cfu's obtained from day 0 and day 5 after treatment were compared. Growth inhibition of Λf. bovis BCG by L- homoserine appears to be bacteriostatic. An additional aspect of the mechanism of action of L- homoserine on slow growing mycobacteria which was evaluated was whether it is bacteriostatic or bacteriocidal. Since tubercle bacilli are capable of entering quiescent states during infection (Gedde- Dahl, Am. J. Hyg., 56:139-214, 1952) and in vitro (Wayne and Sramek, Infect. Immun., 64:2062-2069, 1996) , this question was approached by comparing the ability of M. bovis BCG to survive treatment with L- homoserine as compared with a known bacteriocidal drug, isoniazid, and a known bacteriostatic agent, ethambutol. Surviving colony forming units was measured following a 5-day exposure of M. bovis BCG to L-homoserine, isoniazid, or ethambutol. As may be seen in Figure 5, both the untreated culture and that treated with 200 μg/ml of D-homoserine proliferated by at least a factor of 10 over the 5 day period as measured by colony forming units. In contrast, the numbers of live Λf. bovis BCG recovered from the 5 day cultures treated with 200 μg/ml of L- homoserine or 200 μg/ml of L-homoserine lactone (each at least 4-fold above MIC) were both 9 orders of magnitude less than the number of live Λf. bovis BCG in the starting culture. This level of recovery was similar to that observed for Λf. bovis BCG culture treated with 10 μg/ml of ethambutol (at least 2.5-fold above MIC) and was about 10 times higher than the live Λf. bovis BCG present in the culture treated with 0.1 μg/ml of isoniazid (at
least 4-fold above MIC) . Thus, the inhibitory effect of L-homoserine on Λf. bovis BCG growth is more like the bacteriostatic effect of ethambutol.
Example 6 : Glutamate uptake was assayed with homoserine treated Λf. bovis BCG. Homoserine sensitive and homoserine resistant Λf. bovis BCG strains, which were selected for growth on high concentrations of homoserine and homoserine lactone, were cultured in 7H9 medium in a 37°C horizontal shaker. Bacteria were harvested in the late log phase by centrifugation at 3000 rpm for 5 m. The cell pellet was washed twice with PBS and resuspended in nitrogen-depleted 7H9 broth to its original volume. After an overnight incubation, the bacteria were again harvested and the pellet was resuspended in fresh nitrogen-depleted 7H9 medium. One milliliter portions of the Λf. bovis BCG suspension were transferred to 1.5 ml microfuge tubes and cultured in the presence of PBS or 200 μg/ml of D-homoserine, L-homoserine, or L-homoserine lactone at 37°C with shaking for 2 hr. Λf. bovis BCG were then labeled with 10 μl of 3H-glutamic acid (specific activity of 50 mCi/mmol, Amersham) . After 30 min incubation the glutamate uptake reaction was terminated by immediately chilling the reaction tubes on ice. Cells were spun down quickly in a microcentrifuge at 4°C and washed 3 times with ice-chilled glutamate- containing 7H9 medium. After a final wash, the Λf. bovis BCG pellet was resuspended in 2 ml of liquid scintillation fluid and counted in a scintillation counter for 1 min. Heat-killed (30 min at 80°C) Λf. bovis BCG was used as control for the non-specific
attachment of 3H-glutamate to these bacilli. The dpms from killed Λf. bovis BCG samples were subtracted from the dpms of live Λf. bovis BCG samples. The amount of glutamate taken up by homoserine treated Λf. bovis BCG was presented as the percentage of the untreated controls.
Specific glutamate-uptake inhibition may not be the apparent mechanism for L-homoserine-induced growth inhibition in Λf. bovis BCG. Sritharan et al. (J. Gen. Microbiol., 133:2781-2785, 1987) have shown L-homoserine specifically inhibited glutamate transport in Λf. smegmatis, and addition of L- homoserine inhibited the growth of this saprophytic mycobacterium with an MIC of about 300 μg/ml. To determine whether L-homoserine had similar effect on glutamate transport in Λf. bovis BCG, glutamate uptake assays were performed with Λf. bovis BCG in the presence of L-homoserine. As shown in Figure 6 A, glutamate uptake was inhibited by L-homoserine only at 100 μg/ml or greater. The inhibition was specific for L-homoserine since D-homoserine (Figure 6 A) and L-homoserine lactone (not shown) did not inhibit glutamate uptake in Λf. bovis BCG. Although the degree of inhibition varied among experiments, the average level of glutamate uptake inhibition with 200 μg/ml of L-homoserine was 58% as compared to the PBS treated Λf. bovis BCG cultures (Figure 6 B) . It is unlikely that partial glutamate uptake blockade accounts for the complete growth inhibition by this concentration of L-homoserine on Λf. bovis BCG.
To explore the possibility that the inhibitory effect that L-homoserine had on glutamate transport in Λf. bovis BCG might account for the
growth inhibition induced by this compound, the inhibition of glutamate uptake by L-homoserine was tested in two L-homoserine resistant Λf. bovis BCG mutants, HSR1 and HSR6. These spontaneous mutants were selected on 7H10 agar containing 200 μg/ml of L-homoserine. As may be seen in Figure 6 B, there was no significant difference between the glutamate uptake inhibition by L-homoserine in the sensitive wild type Λf. bovis BCG strain compared with the two L-homoserine resistant Λf. bovis BCG mutants. Thus L- homoserine partially blocks glutamate uptake in both drug sensitive and drug resistant strains. Moreover, the concentrations of L-homoserine at which glutamate transport was inhibited were higher (200 μg/ml) than the MIC of L-homoserine for sensitive Λf. bovis BCG (25-50 μg/ml) . These observations indicate that the inhibitory effect of L-homoserine on glutamate transport cannot completely account for the inhibitory effect of L-homoserine on growth in Λf. bovis BCG.
Example 7 :
The human macrophage cell line, U937 (ATCC CRL 1593; Sundstrom and Nilsson, Intl. J. Cancer, 17:565-577, 1976) , was used for the toxicity assay. U937 cells (human promonocytic cell line) , 5 x IO4 cells per well, were treated with L-homoserine lactone at a concentration of 0, 7.5, 15, 30, 60, 120, 240, or 480 μg/ml in 96-well plates.
Following a 24 hour or 72 hour incubation, U937 cells were labeled with 3H-thymidine for 6 hours. The labeled cells were harvested on a glass fiber filter, lysed and washed with water. After the filter was dry, the radioactivity was measured by
scintillation counting and the amounts of tritium incorporation for the treated groups were compared to the untreated controls at each time point. These results showed that L-homoserine is non-toxic for the human macrophage cell line U937 at levels that are bacteriostatic for mycobacteria.
The principles, preferred embodiments and modes of operation of the present invention have been described in the foregoing specification. The invention which is intended to be protected herein, however, is not to be construed as limited to the particular forms disclosed, since they are to be regarded as illustrative rather than restrictive. Variations and changes may be made by those skilled in the art without departing from the spirit of the invention.
Claims
1. A method for inhibiting growth of a mycobacterium, comprising: administering to a mammal suspected of being infected with said mycobacterium, a growth inhibiting amount of L-homoserine lactone or L-homoserine or a precursor thereof.
2. The method of claim 1, wherein said mycobacterium is a slow growing mycobacterium.
3. The method of claim 2, wherein said slow growing mycobacterium is a species selected from the group consisting of Λf. bovis, Λf. tuberculosis, and multidrug resistant Λf. tuberculosis.
4. The method of claim 2, wherein said slow growing mycobacterium is a tuberculous mycobacterium or a non-tuberculous mycobacterium.
5. The method of claim 1, wherein said mycobacterium is a tuberculous mycobacterium selected from the group consisting of Λf. a fri can uum, Λf. bovis, Λf. microti , and M. tuberculosis .
6. The method of claim 1, wherein said mycobacterium is a non-tuberculous mycobacterium selected from the group consisting of Λf. avium, Λf. intracellulare , Λf. kansasii , and Λf. leprae .
7. The method of claim 1, wherein said precursor is L-homoserine phosphate.
8. A composition for use in the method of claim 1, wherein the composition comprises:
(a) L-homoserine or L-homoserine lactone or a precursor thereof, and (b) an anti-mycobacterial agent.
9. The composition of claim 8, wherein the anti-mycobacterial agent is selected from the group consisting of D-cycloserine, ethambutol, isoniazid, pyrazinamide, rifampin, and streptomycin.
10. A method for inhibiting growth of a slow growing mycobacterium, comprising: administering an effective amount of L-homoserine lactone or L- homoserine or a precursor thereof to inhibit the growth of said mycobacterium.
11. The method of claim 10, wherein said mycobacterium is a tuberculous mycobacterium or a non-tuberculous mycobacteria.
12. The method of claim 10, wherein said mycobacterium is a species selected from the group consisting Λf. africanuum, Λf. avium, Λf. bovis, Λf. intracellulare, M. kansasii , Λf. leprae, Λf. microti , and Λf. tuberculosis.
13. The method of claim 10, wherein said precursor is L-homoserine phosphate.
14. A method of identifying a slow growing mycobacterium, comprising: comparing growth of a clinical specimen in a first cultivation medium with growth in a second cultivation medium comprising an inhibiting molecule selected from the group consisting of L-homoserine, L-homoserine lactone, and a precursor thereof, wherein growth in said first cultivation medium but not in said second cultivation medium indicates the presence of the slow growing mycobacteria.
15. The method of claim 14 wherein said precursor is L-homoserine phosphate.
16. The method of claim 14 wherein said slow growing mycobacteria is a species selected from the group consisting Λf. africanuum, Λf. avium, Λf. bovis, Λf. intracellulare, Λf. kansasii , Λf. leprae, Λf. microti , and Λf. tuberculosis.
17. A cell line, wherein said cell line comprises a slow growing mycobacterium resistant to L-homoserine.
18. The cell line of claim 17, wherein said slow growing mycobacterium is a species selected from the group consisting Λf. africanuum, M. avium, Λf. bovis, Λf. intracellulare, Λf. kansasii , Λf. leprae, Λf. microti , and Λf. tuberculosis.
19. The cell line of claim 17, wherein said slow growing mycobacterium resistant to 200 μg/ml L- homoserine.
20. A method of identifying a gene in a mycobacterium regulated by an anti-mycobacterial agent, comprising: detecting induction or repression of expression of said gene in response to culturing said mycobacterium with L-homoserine or L-homoserine lactone or a precursor thereof.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU18404/97A AU1840497A (en) | 1996-02-01 | 1997-01-31 | L-homoserine and l-homoserine lactone as bacteriostatic agents for m. tuberculosis and m. bovis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1099696P | 1996-02-01 | 1996-02-01 | |
US60/010,996 | 1996-02-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997027851A1 true WO1997027851A1 (en) | 1997-08-07 |
Family
ID=21748405
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/001241 WO1997027851A1 (en) | 1996-02-01 | 1997-01-31 | L-homoserine and l-homoserine lactone as bacteriostatic agents for m. tuberculosis and m. bovis |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU1840497A (en) |
WO (1) | WO1997027851A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6455031B1 (en) | 1997-06-18 | 2002-09-24 | David G Davies | Methods and compositions for controlling biofilm development |
US6756404B2 (en) | 1998-06-18 | 2004-06-29 | The Research & Development Institute, Inc. | Autoinducer compounds |
FR2863168A1 (en) * | 2003-12-04 | 2005-06-10 | Centre Nat Rech Scient | Antibacterial agents comprising gamma--butyrolactone degradation pathway inducers, e.g. succinate semialdehyde, useful in human or veterinary medicine, plant or foodstuff protection or disinfection |
US6936447B1 (en) | 2000-04-03 | 2005-08-30 | University Of Iowa Research Foundation | Autoinducer molecule |
US7442798B2 (en) | 2000-08-31 | 2008-10-28 | The University Of Iowa Research Foundation | Autoinducer molecules and uses therefor |
US7651699B2 (en) | 2001-01-08 | 2010-01-26 | Pathway Intermediates Limited | Autoinducer compounds and their uses |
CN115531364A (en) * | 2021-06-30 | 2022-12-30 | 中国科学技术大学 | Microbial metabolite preparation for preventing or treating rotavirus infection and application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3655510A (en) * | 1968-06-14 | 1972-04-11 | Kyowa Hakko Kogyo Kk | Process for preparing amino acids from hydrocarbons |
-
1997
- 1997-01-31 WO PCT/US1997/001241 patent/WO1997027851A1/en active Application Filing
- 1997-01-31 AU AU18404/97A patent/AU1840497A/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3655510A (en) * | 1968-06-14 | 1972-04-11 | Kyowa Hakko Kogyo Kk | Process for preparing amino acids from hydrocarbons |
Non-Patent Citations (1)
Title |
---|
FEMS MICROBIOLOGY LETTERS, Volume 140, issued 1996, STEAD et al., "Induction of Phenazine Biosynthesis in Cultures of Pseudomonas Aeruginosa by L-N-(3-Oxohexanoyl)Homoserine Lactone", pages 15-22. * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6455031B1 (en) | 1997-06-18 | 2002-09-24 | David G Davies | Methods and compositions for controlling biofilm development |
US7094394B2 (en) | 1997-06-18 | 2006-08-22 | Montana State University | Methods and compositions for controlling biofilm development |
US6756404B2 (en) | 1998-06-18 | 2004-06-29 | The Research & Development Institute, Inc. | Autoinducer compounds |
US7078435B2 (en) | 1998-06-18 | 2006-07-18 | Montana State University | Autoinducer compounds |
US6936447B1 (en) | 2000-04-03 | 2005-08-30 | University Of Iowa Research Foundation | Autoinducer molecule |
US7442798B2 (en) | 2000-08-31 | 2008-10-28 | The University Of Iowa Research Foundation | Autoinducer molecules and uses therefor |
US7651699B2 (en) | 2001-01-08 | 2010-01-26 | Pathway Intermediates Limited | Autoinducer compounds and their uses |
FR2863168A1 (en) * | 2003-12-04 | 2005-06-10 | Centre Nat Rech Scient | Antibacterial agents comprising gamma--butyrolactone degradation pathway inducers, e.g. succinate semialdehyde, useful in human or veterinary medicine, plant or foodstuff protection or disinfection |
WO2005056002A2 (en) * | 2003-12-04 | 2005-06-23 | Centre National De La Recherche Scientifique | Use of inductors of the degradation pathway of gamma-butyrolactone for inactivating the homoserine lactone n-acyl signal of gram-negative pathogenic bacteria |
WO2005056002A3 (en) * | 2003-12-04 | 2006-02-23 | Centre Nat Rech Scient | Use of inductors of the degradation pathway of gamma-butyrolactone for inactivating the homoserine lactone n-acyl signal of gram-negative pathogenic bacteria |
CN115531364A (en) * | 2021-06-30 | 2022-12-30 | 中国科学技术大学 | Microbial metabolite preparation for preventing or treating rotavirus infection and application thereof |
CN115531364B (en) * | 2021-06-30 | 2024-02-23 | 中国科学技术大学 | Microbial metabolite preparation for preventing or treating rotavirus infection and application thereof |
Also Published As
Publication number | Publication date |
---|---|
AU1840497A (en) | 1997-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chu et al. | Quorum quenching bacteria Bacillus sp. QSI-1 protect zebrafish (Danio rerio) from Aeromonas hydrophila infection | |
Smeulders et al. | Adaptation of Mycobacterium smegmatis to stationary phase | |
Degiacomi et al. | In vitro study of bedaquiline resistance in Mycobacterium tuberculosis multi-drug resistant clinical isolates | |
Voskuil et al. | Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program | |
McKinney | In vivo veritas: the search for TB drug targets goes live | |
zu Bentrup et al. | Mycobacterial persistence: adaptation to a changing environment | |
McCune et al. | Microbial persistence: II. Characteristics of the sterile state of tubercle bacilli | |
Zahrt | Molecular mechanisms regulating persistent Mycobacterium tuberculosis infection | |
Chu et al. | Isolation and characterization of new potential probiotic bacteria based on quorum‐sensing system | |
Joly-Guillou et al. | Use of a new mouse model of Acinetobacter baumannii pneumonia to evaluate the postantibiotic effect of imipenem | |
Heifets et al. | Ethambutol MICs and MBCs for Mycobacterium avium complex and Mycobacterium tuberculosis | |
Mor et al. | Inhibitory and bactericidal activities of levofloxacin against Mycobacterium tuberculosis in vitro and in human macrophages | |
Hawke et al. | Fish pasteurellosis of cultured striped bass (Morone saxatilis) in coastal Alabama | |
WO2006029248A2 (en) | Hollow fiber technique for in vivo study of cell populations | |
Nierman et al. | The in vitro antibiotic tolerant persister population in Burkholderia pseudomallei is altered by environmental factors | |
Habte et al. | Mechanisms of persistence of low numbers of bacteria preyed upon by protozoa | |
Rastogi et al. | Activity of clarithromycin compared with those of other drugs against Mycobacterium paratuberculosis and further enhancement of its extracellular and intracellular activities by ethambutol | |
Rastogi et al. | Action of 1-isonicotinyl-2-palmitoyl hydrazine against the Mycobacterium avium complex and enhancement of its activity by m-fluorophenylalanine | |
Wang et al. | Genes and regulatory networks involved in persistence of Mycobacterium tuberculosis | |
Arsene et al. | Prolonged exposure to antimicrobials induces changes in susceptibility to antibiotics, biofilm formation and pathogenicity in Staphylococcus aureus | |
Odenholt et al. | Postantibiotic and bactericidal effect of imipenem against Pseudomonas aeruginosa | |
WO1997027851A1 (en) | L-homoserine and l-homoserine lactone as bacteriostatic agents for m. tuberculosis and m. bovis | |
Yeager et al. | Bacillus anthracis edema toxin suppresses human macrophage phagocytosis and cytoskeletal remodeling via the protein kinase A and exchange protein activated by cyclic AMP pathways | |
Fontes et al. | The acid–base equilibrium of pyrazinoic acid drives the ph dependence of pyrazinamide-induced Mycobacterium tuberculosis growth inhibition | |
Steenken Jr et al. | Mycobacteria Resistant to Hydrazines of Isonicotinic Acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 97527742 Format of ref document f/p: F |
|
122 | Ep: pct application non-entry in european phase |